Belantamab Mafodotin
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
What will happen during the trial?
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 47 patients (estimated)
- Sponsors
- Abramson Cancer Center - University of Pennsylvania (UPENN)
- Collaborators
- GlaxoSmithKline
- Tags
- Antibody Drug Conjugate (ADC), Autologous Stem Cell Transplant, B-Cell Maturation Antigen (BCMA), Maintenance, Post-Autologous Stem Cell Transplant, Pre-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 3 months ago
- SparkCures ID
- 1126
- NCT Identifier
- NCT04680468
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.